Imaging glioblastoma pH using CEST-MRI

Not Applicable

• Conditions: Brain Cancer; Cancer; Malignant neoplasm of brain

• Registration Number: ISRCTN86522205
• Lead Sponsor: niversity of Oxford

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-08-07
• Study Completion: 2021-06-15
• Last Update Posted: 21 July 2021

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 19

Inclusion Criteria

1. Participant is willing, capable of cooperating with the protocol and able to give informed consent for participation in the study
2. Male or female, aged 18 years or above
3. Diagnosed with glioblastoma and scheduled for neurosurgical resection or debulking

Exclusion Criteria

Current exclusion criteria as of 16/02/2018:
1. Intolerant of MRI brain (for example: claustrophobia)
2. MRI brain contraindicated (for example: implanted electric and electronic devices, heart pacemakers, insulin pumps, implanted hearing aids, neurostimulators, intracranial metal clips, metallic bodies in the eye)
3. Neoadjuvant chemotherapy/radiotherapy treatment for glioblastoma which would interfere with the interpretation of trial results
4. Pregnancy
5. Other psychological, social or medical condition that the investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results

Previous exclusion criteria:
1. Intolerant of MRI brain (for example: claustrophobia)
2. MRI brain contraindicated (for example: implanted electric and electronic devices, heart pacemakers, insulin pumps, implanted hearing aids, neurostimulators, intracranial metal clips, metallic bodies in the eye)
3. Prior treatment for glioblastoma
4. Pregnancy
5. Other psychological, social or medical condition that the investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
pH-weighted CEST MRI signal, assessed using amide proton transfer ratio analysis, taken at the patient’s imaging visit